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Tom Vredeveld3, Maria WG Nijhuis van der Sanden4 ,
Raoul HH Engelbert3,5 and Caroline M Speksnijder6
Abstract
Aim: To systematically review the available literature on the diagnostic accuracy of questionnaires and measurement
instruments for headaches associated with musculoskeletal symptoms.
Design: Articles were eligible for inclusion when the diagnostic accuracy (sensitivity/specificity) was established for
measurement instruments for headaches associated with musculoskeletal symptoms in an adult population. The data-
bases searched were PubMed (1966–2018), Cochrane (1898–2018) and Cinahl (1988–2018). Methodological quality
was assessed with the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2) and COnsensus-based
Standards for the selection of health Measurement INstruments (COSMIN) checklist for criterion validity. When pos-
sible, a meta-analysis was performed. The Grading of Recommendations Assessment, Development and Evaluation
(GRADE) recommendations were applied to establish the level of evidence per measurement instrument.
Results: From 3450 articles identified, 31 articles were included in this review. Eleven measurement instruments for
migraine were identified, of which the ID-Migraine is recommended with a moderate level of evidence and a pooled
sensitivity of 0.87 (95% CI: 0.85–0.89) and specificity of 0.75 (95% CI: 0.72–0.78). Six measurement instruments exam-
ined both migraine and tension-type headache and only the Headache Screening Questionnaire – Dutch version has a
moderate level of evidence with a sensitivity of 0.69 (95% CI 0.55–0.80) and specificity of 0.90 (95% CI 0.77–0.96) for
migraine, and a sensitivity of 0.36 (95% CI 0.21–0.54) and specificity of 0.86 (95% CI 0.74–0.92) for tension-type
headache. For cervicogenic headache, only the cervical flexion rotation test was identified and had a very low level of
evidence with a pooled sensitivity of 0.83 (95% CI 0.72–0.94) and specificity of 0.82 (95% CI 0.73–0.91).
Discussion: The current review is the first to establish an overview of the diagnostic accuracy of measurement
instruments for headaches associated with musculoskeletal factors. However, as most measurement instruments
were validated in one study, pooling was not always possible. Risk of bias was a serious problem for most studies,
decreasing the level of evidence. More research is needed to enhance the level of evidence for existing measurement
instruments for multiple headaches.
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Introduction
Primary headaches like tension-type headache (TTH)
and migraine are associated with various musculoskel-
etal factors. TTH is, for example, associated with peri-
cranial tenderness, myofascial trigger points and lower
muscle coordination of the upper neck flexors (1–4).
Furthermore, migraine may be triggered by myofascial
trigger points or bruxism (1,5–7). These primary head-
aches are not caused by musculoskeletal disfunction but
are associated with different musculoskeletal symptoms
(8). There are several secondary headaches that are
actually caused by musculoskeletal problems, such as
cervicogenic headache (CGH), headache after whiplash
trauma and secondary headache attributed to temporo-
mandibular dysfunction (TMD) (8). The physiotherap-
ist (PT) is a specialist in the musculoskeletal field, and
often treats patients with headaches associated with
musculoskeletal symptoms. The type of headache
must be diagnosed within the physiotherapeutic
diagnostic process to choose the proper treatment
options and collaborate with medical specialists when
needed (9).
The International Headache Society (IHS) published
the International Classification of Headache Disorders
– 3rd edition (ICHD-3), which contains clear diagnostic
criteria for all types of headache (8). Several headache
measurement instruments are developed for PTs and
other health care professionals to classify different
headache types (10–14). The ability of a test to discrim-
inate between the target condition and health or not
having the target condition, is called the diagnostic
accuracy of the test (15). The diagnostic accuracy is
often quantified through measures of sensitivity and
specificity (15). Insight into the diagnostic accuracy of
these instruments for headaches associated with muscu-
loskeletal symptoms is needed to determine the type of
headache. Currently there is, to our knowledge, no
overview of diagnostic accuracy of the different head-
ache measurement instruments related to the level of
evidence. Therefore, the aim of this study was to sys-
tematically review the available literature on the diag-
nostic accuracy of questionnaires and measurement
instruments for headaches associated with musculoskel-
etal symptoms.
Methods
Protocol and registration
This review has been performed according to the
PRISMA statement (17) and registered in PROSPERO
(registration number: CRD42017062472). Due to the
magnitude of articles found within the original search
strategy, there were two review questions created.
The focus of the current review is the diagnostic
accuracy of measurement instruments for headaches
associated with musculoskeletal symptoms. A second
review (in preparation) will focus on the clinimetric
properties of the instruments that measure other out-
comes, based on the International Classification of
Functioning, Disability and Health (16); for example,
measurement instruments for pain, range of motion,
limitations in activity, and quality of life.
Eligibility criteria
Only full text original articles were included concerning
the diagnostic accuracy, expressed in sensitivity and
specificity, of diagnostic headache tests usable for
PTs. Further inclusion criteria were: a) adult patients
( 18 years) and b) patients that experienced headaches
associated with musculoskeletal symptoms. These
include migraine, TTH, CGH, headache after whiplash
and headache attributed to TMD (8,19,20). There was
no minimum sample size for inclusion. No restrictions
were put on the year of publication. Intervention stu-
dies, prediction models and measurement instruments
not usable for PTs (e.g. imaging, nerve blocks) (21)
were excluded. Only articles in English were included .
Information sources
The electronic databases PubMed (1966–2018),
Cochrane (1898–2018) and Cinahl (1988–2018) were
searched for literature. The last search was performed
on 25 October 2018. If full texts could not be obtained,
the corresponding author was contacted through email
to request the full text.
Search
The search strategies included search terms for the con-
struct (e.g. pain, diagnosis), the target population (e.g.
migraine, TTH), the instrument (e.g. questionnaire,
test) and the methodological PubMed search filter for
measurement instruments (21). The search filters for the
Cochrane and Cinahl databases were derivatives from
the PubMed search filter. The full search strategies for
each database can be found in Supplemental material 1.
References of retrieved articles were screened for add-
itional relevant studies.
Study selection
Two reviewers (HvdM, CMV) independently assessed
titles, abstracts and reference lists of the studies, using
the online program Covidence (22). In case of disagree-
ment between the two reviewers, a third reviewer
(CMS) made the decision regarding inclusion of the
article. After initial screening of the titles and abstracts,
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HvdM and CMV read the full texts of included articles
and screened these for eligibility. All reviewers are oro-
facial physiotherapists and researchers in this field.
Data collection process
Two reviewers (HvdM, CMS) independently extracted
data from the included articles and registered this in a
pre-made, empty Table 1 format. The data extracted
were: First author, year of publication, target popula-
tion, information about the index test (aim, language
and name), reference test, study population, diagnostic
accuracy (sensitivity/specificity).
Risk of bias in individual studies
The methodological quality of the included studies was
assessed using the Quality Assessment of Diagnostic
Accuracy Studies tool (QUADAS-2) (23,24). This tool
assesses the risk of bias within four domains: Patient
selection, index test, reference standard, and flow and
timing (24). Concerns regarding applicability were also
determined for the first three domains (24).
Methodological quality of studies regarding the criterion
validity was assessed using the COSMIN checklist (25).
Criterion validity is defined as the degree to which the
scores of an instrument are an adequate reflection of a
gold standard (26). Within diagnostic accuracy, criterion
validity is an essential measurement property. For criter-
ion validity, box H of the COSMIN was used (25).
Data extraction and assessment of methodological
quality were performed by two reviewers independently
(HvdM, CMS). HvdM was trained to use the QUADAS-
2 tool and CMS was trained by the COSMIN team on
quality appraisal and data extraction. The protocol for
methodological assessment using the QUADAS-2 tool
for this review was made available for the review authors
(Supplemental material 2). The protocol for the
COSMIN checklist is published elsewhere (25).
Summary measures
Sensitivity and specificity were used as measures of
diagnostic accuracy.
Synthesis of results
A best evidence synthesis was performed using the
GRADE recommendations for diagnostic accuracy stu-
dies with the GRADE pro online software (27). These
recommendations provide a step-by-step assessment to
determine the certainty of evidence of a diagnostic test,
which results in a comprehensive and transparent
approach for developing the recommendations for
these tests. To determine the impact of the test, both
the sensitivity and specificity of the test must be known
as well as the prevalence of the target condition (27).
Based on the prevalence of the target population, the
pre-test probability of the presence of the headache was
determined for a population of 1000 people (27) . The
test sensitivity and specificity was used to determine
how many people would be accurately diagnosed
(true positive) or excluded from having the headache
(true negative).
A pooled sensitivity and specificity was used for each
measurement instrument when there were multiple stu-
dies for one measurement tool. The pooled measure-
ments were calculated using the ‘rmeta’ package for
the R statistical software (28). A bivariate model result-
ing in a summary estimate for sensitivity and specificity
together was used, as recommended by the Cochrane
Collaboration (29,30). This model takes potential
threshold effects and the correlation between sensitivity
and specificity into account (29,30). The pooled sensi-
tivity and specificity were used for the GRADE recom-
mendations. When there was only one study for a
measurement instrument, the published sensitivity and
specificity of that measurement instrument were used.
Finally, a summary receiver operating characteristics
(S-ROC) curve was created using the ‘mada’ package
for the R statistical software (29,31,32).
Factors determining the quality of evidence accord-
ing to the GRADE approach are: a) Limitations in
study design or execution (risk of bias); b) inconsistency
of results; c) indirectness of evidence; d) imprecision;
and e) publication bias (27). For limitations, the
risk of bias assessment from the QUADAS-2 was
used to determine if downgrading of the evidence was
needed. When 50% of the assessed domains scored a
‘‘high’’ or ‘‘unclear’’ risk of bias, this was considered
‘‘serious’’ and the level of evidence was downgraded by
one. When 75% of the assessed domains scored a
‘‘high’’ or ‘‘unclear’’ risk of bias, this was considered
‘‘very serious’’ and the level of evidence was down-
graded by two. Inconsistency refers to unexplained het-
erogeneity of the results between multiple studies, after
which the level of evidence may be downgraded. The
indirectness of evidence was determined by the applic-
ability assessment of the QUADAS-2 tool with the
same rules as the risk of bias assessment. In the case
where there was only one article studying a measure-
ment tool, the evidence was downgraded for impreci-
sion. All steps of the synthesis of results are depicted in
Figure 1.
Risk of bias across studies
Methods to detect publication bias are not very reliable
in diagnostic accuracy studies (30). As diagnostic accur-
acy studies have sensitivity and specificity values as
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outcome measures rather than a stated null hypothesis
with a p-value, it is unlikely for publication bias to be
associated with statistical nonsignificance (33).
Therefore, no publication bias assessment was applied
in this review.
Results
Study selection
The search in all three databases resulted in 4129 art-
icles, which were imported in Covidence (22). After
removing duplicates and assessment of eligibility on
title/abstract, 150 articles remained to be assessed full
text. Of these, 52 articles were excluded based on the
inclusion and exclusion criteria (Supplemental material
3) and 67 articles assessed other clinimetric outcome
measures than diagnostic accuracy. These 67 articles
will be included in the second review regarding clini-
metric outcome measures based on the ICF. This
resulted in 31 articles to be included in the current
review. The complete flowchart of the study selection
can be found in Figure 2. No authors were contacted to
obtain the full texts of any study.
Study characteristics
The included headaches associated with musculoskel-
etal symptoms in this review are migraine, TTH and
CGH. No measurement instruments were found that
studied the diagnostic accuracy for instruments related
to secondary headache attributed to TMD or headache
attributed to whiplash injury. Table 1 shows the study
characteristics of the 31 included studies, stratified by
target population of the measurement instrument.
From the 31 studies, 22 articles had migraine as the
target population (10–12,34–51). Seven articles had
both migraine and TTH as target population
(13,14,52–56), and two articles examined patients with
CGH (57,58). In total, 28,246 people were included in
the 31 studies. Of the included population, 64% were
female, though three articles did not describe the gender
distribution (38,54,55). Mean age varied from 19 (42) to
52 years (53).
For migraine, 11 different measurement instru-
ments were studied (10–12,34–37,40–43,44–51,59).
ID-Migraine was the most studied measurement instru-
ment, with nine studies in five languages (12,34,40,
44–47,49,50). Eight of these instruments were screening
instruments, one was a replacement test for the diag-
nostic process, and for two instruments the aim of the
test was unclear. Out of the seven studies for both
migraine and TTH, only two articles looked at the
same questionnaire (13,56). From the seven instru-
ments, one was a screening test, three were replacement
tests, and the aim of two was unclear. Both studies on
CGH researched the cervical flexion-rotation test
(CFRT) (57,58). The aim of the CFRT compared to
the ICHD-3 criteria for cervicogenic headache is
unclear.
Included articles (N = 31)
Quality assessment
COSMIN
box H
Applying GRADE criteria 
QUADAS-2
Certainty of evidence per measurement instrument
mela-
analysis
(n = 10)
Single
outcomes
(n = 21)
Statistical analyses
Figure 1. Flow of steps after article inclusion.
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Risk of bias within studies
The risk of bias was assessed for patient selection, index
test, reference standard and flow and timing. The sum-
marized assessment of the QUADAS-2 can be found in
Table 2. The complete assessment, including reasons
for the given scores, can be found in Supplemental
material 4. Only one study received a low risk of bias
on all domains (43). Twenty-two articles received a
‘‘high’’ risk of bias on 1 domain (10–14,35,37,
39–41,43,45–50,55–59). The remaining articles received
an ‘‘unclear’’ risk of bias on 1 domain (12,35,37,
41,50–53). Risk of bias for the index test and the refer-
ence standard was generally scored unclear, because
there was uncertainty if the index test was conducted
and interpreted without knowledge of the results of the
reference standard.
The clinimetric evaluation of the criterion validity
was established with the COSMIN Box H. One study
scored excellent (14), one good (35), 21 fair
(11,12,34,36–48,50–53,57) and the remaining eight
scored poor (10,13,50,55–57,59). Of the studies scoring
poor, all but two (54,55) also scored a high risk of bias
on 2 domains (10,12,13,50,55,57,59).
Migraine measurement instruments
Results of individual studies. The sensitivity of the meas-
urement instruments for migraine ranged from 0.38
(38) to 0.99 (48) (see Table 1). Only three studies had
a sensitivity below 0.70 (38,41,50) and eight studies
found a sensitivity of 0.90 or higher (11,39,42,44,
45,47–49). Half of these studies with a high sensitivity
were researching the ID-Migraine (44,45,47,49).
Specificity ranged from 0.27 (10) to 0.99 (37). Six stu-
dies found a specificity of 0.70 or lower (10,39,43,45,
47,49), and a specificity above 0.90 was found in six
other studies (38,41,42,48,50,51). Eleven studies had
both sensitivity and specificity above 0.70 (11,12,34,
35,40,42,44,46,48,51,59), of which two studies had
both above 0.90 (42,48).
4129 references imported from Pubmed, Cinahl and 
cochrane for screening
3999 studies screened for eligibility against title and 
abstract
150 studies assessed for full-text eligibility
98 studies assessed for type of measurement tool
31 studies included in diagnostic accuracy
review10–14,34–59
130 duplicates removed
3849 studies excluded
52 studies excluded: 
• 25 no clinimetrics 
• 9 not within the PT domain 
• 6 not the original research paper 
• 5 double 
• 2 no full-text available 
• 2 not focused on headache evaluation 
• 2 wrong patient population 
• 1 wrong language
67 studies excluded current review, 
included in second review 
Figure 2. Study flow diagram.
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Synthesis of results. For two measurement instruments,
the sensitivity and specificity could be pooled. For the
3-question Screen the pooled sensitivity was 0.73 and
specificity was 0.93 (Table 3) based on two (10,41) out
of three studies, due to missing data in one article (59).
The pooled sensitivity for the ID-Migraine was 0.87 and
specificity was 0.75 (Table 3, Figures 3(a) and 3(b)). The
results were based on four studies (34,40,47,49) as the
other five studies (12,44–46,50) did not have sufficient
data available to perform the analyses.
There was a very low level of evidence for six meas-
urement instruments for migraine related to the GRADE
recommendations: Diagnostic Screen (37), Michel’s
Standardized Migraine Diagnosis Questionnaire (38),
Migraine Specific Questionnaire (48), Migraine-4 (42),
Modified Algorithm for IHS Migraine (36), Screening
Items (43), and the Structured Migraine Interview
Questionnaire (see Table 4) (39). For two measurement
instruments, there was a low level of evidence: The 3-
question Screen (10,41) and the Migraine Screen
Questionnaire (11,51). There was a moderate level of evi-
dence for the ID-Migraine (34,40,47,49) and also for the
Migraine Assessment Tool (35).
Combined migraine and TTH measurement
instruments
Results of individual studies. The aim of the index tests
differed between the included seven articles, where
four were ‘replacement’ tests (13,54–56), one a ‘triage’
test (14) and two aims were unclear (52,53). Three art-
icles established the diagnostic accuracy for several
migraine and TTH ICHD diagnoses aside from the
‘‘standard’’ diagnoses, including chronic migraine,
chronic TTH, probable migraine, and probable TTH
(14,52,53). For migraine, the sensitivity ranged from
0.49 (53) to 1.00 (54) and the specificity ranged from
0.85 (56) to 0.96 (13). For chronic migraine, the sensi-
tivity and specificity were 0.71 and 0.98 respectively
(52). Probable migraine had a sensitivity of 0.89 and
a specificity of 0.54 (14). The sensitivity for TTH
ranged from 0.36 (14) to 1.00 (54) and the specificity
range was 0.69 (53) to 0.98 (13). One study did not
establish the specificity results from their test (54).
Chronic TTH was tested in two studies, for which the
sensitivity was 0.64 (53) to 0.70 (52) and the specificity
0.96 (52) to 1.00 (53). The test for probable TTH had a
sensitivity of 0.92 and a specificity of 0.48 (14).
For migraine, chronic migraine, and probable
migraine (13,14,52,54,56) five studies had a sensitivity
above 0.70, which was also found for TTH, chronic
TTH, and probable TTH in five studies (see Table 1)
(13,14,52–54). All six studies that reported specificity,
had a specificity of 0.70 or higher for migraine, chronic
migraine, and probable migraine and for TTH chronic
TTH, and probable TTH (13,14,52,53,55,56).
Synthesis of results. One instrument, the German
Language Questionnaire, was supported by two studies
(13,56). The pooled sensitivity and specificity for
migraine were 0.69 and 0.90 respectively (Table 3,
Figure 3(c)). For TTH, the pooled sensitivity and spe-
cificity were 0.81 and 0.96 respectively (Table 3,
Figure 3(d)). The five other measurement instruments
(14,52–55) were supported by one study and therefore
downgraded for imprecision (see also Table 5).
There was a very low level of evidence for the
Computerized Headache Assessment Test (CHAT)
(54), the use of Headache Questions (53) and the
Structured Headache Questionnaire (52). The German
Language Questionnaire (13,54) and the Self-
Administered Headache Questionnaire (55) are both
supported with a low level of evidence. Only the
Headache Screening Questionnaire (HSQ)– Dutch
Table 3. Pooled sensitivity and specificity of the 3-Question screen, ID-Migraine, German language questionnaire and Cervical
Flexion-Rotation Test.
Measurement instrument Target population
Number of studies;
author, year
Pooled sensitivity
(95% CI)
Pooled specificity
(95% CI)
3-Question screen Migraine 2; Cady, 2004 (10)
Wahab, 2016 (41)
0.73 (0.71–0.75) 0.93 (0.9–0.94)
ID-Migraine Migraine 4; Lipton, 2016 (34)
Siva, 2008 (40)
Gil-Gouveia, 2009 (47)
Karli, 2007 (49)
0.87 (0.85–0.89) 0.75 (0.72–0.78)
German language
questionnaire
Migraine
TTH
2; Fritsche, 2007 (13)
Yoon, 2008 (56)
0.69 (0.63–0.75)
0.81 (0.75–0.87)
0.90 (0.86–0.94)
0.96 (0.94–0.98)
Cervical Flexion-
Rotation Test
Cervicogenic
headache
2; Hall, 2010 (57)
Ogince, 2007 (58)
0.83 (0.72–0.94) 0.82 (0.73–0.91)
N: number; CI: confidence interval; TTH: tension-type headache.
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Version was found to have a moderate level of
evidence (14).
Cervicogenic headache measurement instruments
Results of individual studies. The two included studies for
CGH established the diagnostic accuracy of
the Cervical Flexion-Rotation Test (CFRT) (57,58).
Both sensitivity and specificity ranged from 0.70 (57)
to 0.91 (58).
Synthesis of results. The pooled sensitivity was 0.83 and
the pooled specificity was 0.82 (Table 3, Figure 3(e)).
Based on the GRADE recommendations (Table 6),
there is a low level of evidence for the use
of the CFRT for patients with cervicogenic
headache (57,58).
Discussion
Within this review, for migraine alone 11 tools were
identified (10–12, 34–37,40–51,59), for the combination
S-ROC for 3question screen(a)
(b) (c)
(e)(d)
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Figure 3. (a) Summary Receiver Operating Characteristics (S-ROC) curves for pooled sensitivity and specificity of the 3-question
screen; (b) S-ROC curves for pooled sensitivity and specificity of the ID-migraine; (c) S-ROC curves for pooled sensitivity and
specificity of the German questionnaire for migraine; (d) S-ROC curves for pooled sensitivity and specificity of the German ques-
tionnaire for tension-type headache; (e) S-ROC curves for pooled sensitivity and specificity of the cervical flexion rotation test.
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1326 Cephalalgia 39(10)
of migraine and TTH six (13,14,52–56), and for CGH
one tool (57,58). The sensitivity and specificity of the
measurement instruments for migraine ranged from
0.38 (38) to 0.99 (48) and 0.27 (10) to 0.99 (37) respect-
ively. The sensitivity and specificity for migraine based
on the combined measurement instruments ranged
from 0.49 (53) to 1.00 (54) and 0.85 (56) to 0.96 (13)
respectively. For TTH, the sensitivity and specifi-
city ranged from 0.36 (14) to 1.00 (54) and 0.59
(53) to 0.98 (13) respectively. For the CFRT, the only
measurement instrument for cervicogenic headache,
both the sensitivity and specificity ranged from 0.70
(57) to 0.91 (58). All measurement tools for migraine
and TTH were questionnaires. The measurement tool
for CGH was a physical examination test. Migraine
and TTH are solely based on information from the his-
tory of the patient (15), allowing the diagnosis to
be derived from a questionnaire. However, the choice
of gold standard within headache research is inconsist-
ent. Some studies used the International Classification
of Headache Disorders (ICHD) first, second or
third edition (15,60,61), others used the diagnosis of a
neurologist or a headache nurse and for CGH the
Sjaastad criteria were used (62). As the ICHD is
based on the most recent scientific findings and clinical
expertise from experts worldwide, the newest version of
the ICHD is recommended as the gold standard
(15,63).
The aim of each measurement instrument is
described in Table 1. This was unclear for five measure-
ment instruments. Nine measurement instruments are
meant to be used as a screening tool in a broader popu-
lation before seeing a medical specialist for a definitive
diagnosis. These screening instruments are recom-
mended for health care providers like PTs, as they are
not trained for medical diagnoses but do see these
patients often and can refer them to the medical spe-
cialist (64). Three measurement instruments studied
were meant as a replacement test for the gold standard.
This may be efficient for research purposes, as this
allows the researchers to diagnose the patients without
an extensive visit to a specialist. However, no conclu-
sion was drawn from the included articles as to whether
the measurement instruments were better than the gold
standard (the medical specialist), therefore the presence
of a medical specialist is still recommended in clinical
practice.
For each measurement tool, the cut-off criteria to
recognize headache should be described to allow for
comparison of outcomes between studies. In reality,
cut-off criteria differed between studies, which resulted
in highly variable sensitivity and specificity. The lack of
established cut-off points was taken into account within
the ‘Index Test’ domain when assessing both methodo-
logical qualities and risk of bias.T
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Migraine measurement instruments
From the 11 measurement instruments found for
migraine, only three were supported by evidence of
two or more articles: The 3-question screen (10,41,59),
the ID-migraine (12,34,40,44–47,49,50) and the
Migraine Screen Questionnaire (11,51). Several studies
introduced serious patient selection bias by only
recruiting patients with the headache they were inter-
ested in studying (10). By doing so, there were no false
positives or true negatives present, which resulted in
more favourable diagnostic accuracy outcome meas-
ures. Other studies excluded participants who had a
secondary headache (45), or who did not screen positive
for a preliminary screening for migraine (45,46,49). One
study selected their participants so 50% had a con-
firmed migraine diagnosis prior to the index test and
50% did not have migraine (11). This also introduced
selection bias in favour of the outcomes, as the preva-
lence of the studied disorder (50% in the tested group
versus 14.7% in the general population) determines the
pre-test probability and thus the chance of correct diag-
nosis (65,66).
Furthermore, serious bias was introduced in the
‘‘flow and timing’’ section of the articles, as some art-
icles did not properly describe the order of receiving the
index test and the reference standard diagnosis. Other
studies did not include all participants in the analysis
(11,12,34,37,38,40,42,43,48,49,59). The introduced
biases on both domains resulted in a downgrade of
the certainty of evidence on all measurement instru-
ments except for the Migraine Assessment Tool (35).
However, as this tool is only studied in one article, the
level of evidence was also downgraded for imprecision.
Therefore, there are no measurement instruments for
migraine with a high level of evidence.
Combined migraine and TTH measurement
instruments
Out of the six measurement instruments that looked at
both migraine and TTH, only the German language
questionnaire is supported by two articles (13,57).
However, due to a serious risk of bias and indirectness,
there is only a low level of evidence for this question-
naire. In both studies, only patients with headaches that
were also studied in the questionnaire were included,
which introduced a serious selection bias (13,57).
Similarly, the Computerized Headache Assessment
Tool (CHAT) presented a sensitivity of 1.00 for both
migraine and TTH, but no true negatives or false posi-
tives were available, and no specificity was presented
(54). In this study, the gold standard was the diagnosis
established by a headache nurse (54). As stated before,
this is an unreliable gold standard for a headache diag-
nosis (63).
The seven articles differed in population. Some study
samples were retrieved from the general population
(53,55,56), others from urgent care or family practice
(54), and others from a headache clinic (13,14). In one
study, the sample origin was unclear (52). The preva-
lence used in the GRADE recommendations was for
the general population, but in health care settings the
prevalence is higher. This increases the pre-test prob-
ability of a positive headache diagnosis. This must be
taken into consideration when interpreting the results
of those studies (14,54,56).
Regarding the flow and timing of these studies, not
all participants received both the index test and refer-
ence standard (52–54,56). Other studies did not include
all participants in the final analyses (13,14,53,55). By
excluding participants in these ways, the generalization
of results is compromised. All these components
resulted in very low to moderate level of evidence for
the six combined migraine and TTH measurement
instruments.
Cervicogenic headache measurement instruments
Both articles studying the diagnostic accuracy of the
cervical flexion rotation test (CFRT) for CGH
showed selection bias, as participants were selected
based on headache type (57,58). In one study, the sen-
sitivity and specificity were both 0.70 (57), whereas in
the other study the sensitivity was 0.91 and the specifi-
city 0.90 (58). In the study with lower diagnostic accur-
acy, the control group consisted of other headache
forms (migraine or multiple headache forms) (57).
This makes differentiating between headache types
more difficult as other headaches are related to neck
problems (5,67,68). The study with higher diagnostic
accuracy compared patients with CGH with asymp-
tomatic participants and several patients with migraine
(58), which made it easier to recognize the CGH. When
this test is applied in the clinic, patients will have a
headache complaint and will not be asymptomatic, so
the sensitivity and specificity of 0.70 will likely be more
accurate.
Just as in the current review, another recent system-
atic review describing physical examination tests for
screening and diagnosis of CGH, the CFRT was deter-
mined to be the most useful test with the highest reli-
ability and strongest diagnostic accuracy (69). There is,
however, a debate in the literature on the reliability of
manual ROM tests of the spine (70). Inter-examiner
reliability for the cervical spine passive ROM ranged
from poor to substantial. The manual tests of the
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upper cervical spine (C1/2, C2/3) have a fair to substan-
tial level of reliability (70). The reliability of the CFRT
has been established to be good to excellent (71).
However, CFRT reliability was established by compar-
ing a manual diagnosis of C1/2 dysfunction with the
outcome of the CFRT (71). If the reliability of the man-
ual diagnosis of dysfunction is only fair, then the reli-
ability of the CFRT is questionable. However, in
another study where the cervical ROM was measured
with a device (CROM), a significant difference was
found between the ROM in patients with CGH com-
pared to patients with migraine and healthy subjects,
which confirms the findings of the included papers of
this review (57,58,72). In conclusion, the CFRT is a
valid and reliable measure to recognize CGH, though
the reliability is higher when using a CROM device
rather than assessing the ROM manually.
Strengths and limitations of the study
The current review is, to the authors’ knowledge, the
first review establishing an overview of the diagnostic
accuracy of measurement instruments for headaches
associated with musculoskeletal symptoms. By using
the QUADAS-2 and COSMIN tool, the methodo-
logical quality was assessed in a well-known and inter-
nationally accepted manner (24,25). By using the
GRADE recommendations, the findings of this review
are transparent and easy to translate to the clinical
practice (27).
There are, however, also a few limitations of this
study. Comparison between index and reference test
was not easy, as the validation of the index test was
performed in a different population compared to the
population in which the reference standard was devel-
oped. It is important to keep in mind that the diagnos-
tic accuracy is dependent on the prevalence of the target
condition in the population; the study sample needs to
be taken into consideration when interpreting the
results. The prevalence of the target condition is the
pre-test probability of a person having that condition,
and a good measurement instrument will increase the
chance of recognizing the target condition correctly.
However, if the study sample is biased by having a
very high prevalence in the target condition whereas
the measurement instrument would normally be used
in a setting with a low prevalence of the target condi-
tion, the diagnostic accuracy is not valid for that spe-
cific population. Validation studies of measurement
instruments should therefore always test the measure-
ment instrument in the population and setting for
which it is being validated.
Also, some measurement tools were used in different
languages and cultures, which must also be considered
when interpreting these results. In this review, great
variability was found between the different studies, as
illustrated in the S-ROC curves in Figure 3(a) and (c).
These S-ROC curves show the uncertainty of the find-
ings compared to reality, so the pooled data should be
used with caution. The clear gap between the diagnostic
accuracy of some measurement instruments between
studies showed the necessity of conformation by mul-
tiple studies within the same population and against the
same reference standard.
Implications for practice
The findings of the current review support the use of the
ID-Migraine questionnaire to diagnose migraine with a
moderate level of certainty (Table 4). However, patients
with headaches often experience multiple headache
forms (7,13,74). This warrants a measurement instru-
ment that can diagnose more than one headache. From
the questionnaires that looked at both migraine and
TTH, the HSQ has the highest level of evidence
within this review (Table 5). To establish if there is a
migraine and/or a TTH present, this questionnaire is
therefore recommended. As CGH needs to be con-
firmed by physical examination (15), the CFRT is rec-
ommended (Table 6). No other measurement
instruments for secondary headache related to muscu-
loskeletal complaints were found. Therefore, for these
headache types, such as secondary headache attributed
to temporomandibular disorders or headache attribu-
ted to whiplash injury, no recommendations can
be made.
Implications for future research
Currently, there are many questionnaires for migraine
and TTH, most of them validated by one study. Future
research should use the recommended measurement
instruments and validate them in different samples of
the same population to increase the level of certainty
that the diagnostic accuracy is realistic. The QUADAS-
2 and COSMIN tools should be used when designing
their studies to enhance their methodological quality.
Furthermore, additional clinimetric properties of
measurement instruments for headache should be
examined. Clinimetric properties such as reliability
and responsiveness are important to enhance the care
of headache complaints and monitor the course of these
complaints. For that reason, the authors are conduct-
ing a complementary review to establish the clinimetric
properties of measurement instruments for these symp-
toms and factors (Figure 2).
In conclusion, only a few measurement instruments
reached a moderate level of evidence for the diagnostic
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accuracy. For migraine, the ID-Migraine is recom-
mended. For migraine and TTH, the HSQ is recom-
mended, and the CFRT is advised to be used for
CGH. However, more studies are needed to validate
these instruments further to enhance the level of
evidence.
Article highlights
. ID-migraine is the most studied diagnostic accuracy measurement instrument for migraine and has a
moderate level of certainty.
. Six measurement instruments are examined that establish the diagnostic accuracy for both migraine and
tension-type headache.
. The Headache Screening Questionnaire has the highest level of evidence to screen for both migraine and
tension-type headache.
. Only the Cervical Flexion Rotation Test studies the diagnostic accuracy for cervicogenic headache, but the
level of evidence is very low.
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